The invention discloses an OCTS technology-based
pancreatic cancer and malignant
mesothelioma CAR-T therapy vector. The vector comprises
lentivirus framework
plasmid, a human EF1alpha
promoter (SEQ ID NO. 14), an OCTS chimeric
receptor structural domain and a PDL1 single-chain
antibody; the OCTS chimeric
receptor structural domain comprises CD8 leader chimeric
receptor signal peptide (SEQ ID NO. 15), a PDL1 single-chain
antibody light chain VL (SEQ ID NO. 16), a PDL1 single-chain
antibody heavy chain VH (SEQ ID NO. 17), an
MESOTHELIN single-chain antibody light chain VL (SEQ ID NO. 18), an
MESOTHELIN single-chain antibody
heavy chain VH (SEQ ID NO. 19), an antibody inner
linker Inner-
Linker (SEQ ID NO. 20), a single-chain antibody inter-
linker Inter-
Linker (SEQ ID NO. 21), a CD8 Hinge chimeric receptor
linker (SEQ ID NO. 22), a CD8Transmembrane chimeric receptor
transmembrane domain (SEQ ID NO. 23), a TCR chimeric receptor T-
cell activation domain (SEQ ID NO. 26), and a chimeric receptor inducible co-stimulater area. In addition, the invention also discloses a construction method of the vector as well as application of the vector to preparation of medicines for treating
pancreatic cancer and malignant
mesothelioma.